source
- Sarepta CEO Sees Path to Stronger DMD Trials Amid 2025 Elevidys SetbacksSarepta Therapeutics’ newly appointed chief executive Michael Severino, after a 90‑day assessment period, outlined a plan to restore the company’s leadership in the Duchenne muscular dystrophy mark…
- Podcast examines Democrats' midterm win and concerns over a costly, questionable fertility genetic procedureStat's weekly biotech podcast "The Readout LOUD" released an episode featuring Washington correspondent Daniel Payne to discuss how the Democrats' sweeping midterm victory could shape drug pricing…